By Stephen Nakrosis
Biopharmaceutical company Kairos Pharma filed for an initial public offering with the Securities and Exchange Commission.
The company said it is working on therapeutics for cancer patients designed to “overcome key hurdles in immune suppression and drug resistance.”
Its drug candidate portfolio currently consists of a pipeline of seven candidates, “including KROS drugs, which are immunotherapeutics, and ENV antibodies, which are designed to reverse drug resistance that often results as a consequence of the use of cancer therapeutics,” Kairos said.
The company didn’t give an expect size for its IPO, nor did it offer an expected price range.
Kairos applied to list on The Nasdaq Capital Market under the symbol KAPA.
Boustead Securities, LLC is listed as the offering’s underwriter.
Write to Stephen Nakrosis at [email protected]
Read the full article here